Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 17/20 | 0.78 |
| ▸ | EGFR known ✓ | P00533 | 13/20 | 0.78 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.78 |
| ▸ | FLT1 known ✓ | P17948 | 15/20 | 0.66 |
| ▸ | FGFR1 known ✓ | P11362 | 11/20 | 0.65 |
| ▸ | FLT4 known ✓ | P35916 | 10/20 | 0.65 |
| ▸ | PDGFRB known ✓ | P09619 | 3/20 | 0.65 |
| ▸ | FGFR3 known ✓ | P22607 | 2/20 | 0.64 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.64 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.64 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.64 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.64 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.64 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.64 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.64 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.64 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.64 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.64 |
| ▸ | BCR known ✓ | P11274 | 1/20 | 0.64 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159652 | 0.99 | KDR (0.80) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL1782686 | 0.93 | KDR (0.68) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL2139091 | 0.90 | EGFR (0.67) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL7864775 | 0.90 | KDR (0.98) | KDREGFRRETKIF5BFLT1 | |
| Hydrochloric Acid SCHEMBL1467888 | 0.89 | FLT1 (0.82) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL5864525 | 0.89 | KDR (1.00) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL18979021 | 0.88 | FLT1 (0.84) | KDREGFRFLT1FGFR1FLT4 | |
| SCHEMBL2137462 | 0.88 | EGFR (0.64) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL17520323 | 0.88 | KDR (0.74) | KDREGFRRETKIF5BFLT1 | |
| SCHEMBL19006858 | 0.87 | KDR (0.87) | KDREGFRRETKIF5BFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2021-09-09 | — | — | US | disclosed |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | GENZYME CORPORATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | GENZYME CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2016-05-12 | — | — | US | disclosed |
| US-9040548-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2015-05-26 | — | — | US | disclosed |
| CN-102503898-B | Chemical process for preparing quinazoline derivatives | ASTRAZENECA SWEDEN AB | 2015-03-25 | — | — | CN | disclosed |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | ASTRAZENECA AB (SE) | 2014-05-01 | — | — | US | disclosed |
| US-8642608-B2 | Quinazoline derivatives as VEGF inhibitors | ASTRAZENECA AB (SE) | 2014-02-04 | — | — | US | disclosed |
| EP-1244647-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | AstraZeneca AB (SE) | 2002-10-02 | — | — | EP | disclosed |
| US-6414148-B1 | PRODUCE ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT IN WARM-BLOODED ANIMALS | ZENECA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| EP-0885198-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-12-19 | — | — | EP | disclosed |
| WO-2001077085-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
| US-6291455-B1 | PRODUCING AN ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY REDUCING EFFECT | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| WO-2001032651-A1 | QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
| EP-0929530-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| EP-0885198-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1998-12-23 | — | — | EP | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| WO-1997032856-A1 | 4-ANILINOQUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099946-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | KDR 3/4885EGFR 199/4885RET 503/4885 |
| US-20210276972-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 207/4885RET 624/4885 |
| US-10457664-B2 | Quinazoline derivatives as VEGF inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885RET 509/4885 |
| US-20160130249-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885RET 446/4885 |
| US-20140121228-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT4, FLT1, KDR | KDR 3/4885EGFR 120/4885RET 583/4885 |
| US-20200262811-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 181/4885RET 446/4885 |
| US-20190002433-A1 | Quinazoline Derivatives as VEGF Inhibitors | FLT1, FLT4, KDR | KDR 3/4885EGFR 179/4885RET 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.